Surprising finding from world-first study of prostate cancer survival

A LANDMARK 10-year trial in men with PSA-detected localised prostate cancer has found surprisingly low mortality whether the patients received surgery, radiotherapy or watchful waiting.

However the study, ProtecT, the first randomised controlled trial (RCT) of its kind with long-term data, still doesn’t clarify the best choice for patients and more follow-up is needed, its authors say.

The evidence does show, however, that watchful waiting compared with treating early disease leads